Alvotech Reports Q4 and FY25 Revenue Growth, Reaffirms 2026 Guidance

Alvotech reported Q4 and FY25 revenue growth, with adjusted EBITDA increasing 218.8% to $69mln and total revenue up 12.9% to $173.2mln. The firm reaffirmed its 2026 outlook, expecting revenue of $650-$700mln and adjusted EBITDA of $180-$220mln. Alvotech anticipates receiving US FDA approval for four Biologics License Applications by late 2026. The stock is up 2.11% in pre-market trading.